The size of the Asia-Pacific Cancer Vaccines Market was worth USD 0.63 billion in 2020 and estimated to reach USD 1.46 billion by the end of 2025, growing at a CAGR of 18.24% between 2020 to 2025.
Cancer vaccines are one of the revolutionary innovations that could relieve the pains and sufferings from cancer. The cancer vaccine has changed a lot the idea and methodology of treating cancer. It is the mixture of new proteins from tumor regions mixed with immune cells, which can easily and specifically recognize and attach to the tumors. It is also getting so much attention due to its characteristic properties such as low toxicity, fewer side effects, and high specificity.
Asia-Pacific cancer vaccines market is primarily driven by the rising number of people with cancer, increasing public awareness of vaccines, smoking and excessive alcohol intake, strong late-stage pipeline Vaccines, vendors' patient-assistance programs the major factors driving the growth of the market. Stringent regulations for the approval, Vaccine costs are the factors limiting the growth of the market.
Based on Cancer type, the market is segmented into Prostate, Cervical, Anal, Throat, and others. Based on the Vaccine type, the market is segmented into Protein and Peptide-based, Tumour cell, Dendritic cell, Genetic vaccines, and Others. Based on End Users, the market is segmented into Cancer Treatment Centres and Research Institutes. Based on Geography, the Asia-Pacific Cancer Vaccines market is analyzed under various regions, namely China, India, Japan, South Korea, and Australia.
Major players influencing the Asia-Pacific cancer vaccines market are Dendreon, GlaxoSmithKline, and Merck. Companies with their products in the pipeline are Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, AVAX Technologies, Bavarian Nordic, Biothera, Celldex Therapeutics, CureVac, Galena Biopharma, Genexine, GlobeImmune, Gradalis, Heat Biologics, Immatics, ImmunoCellular Therapeutics, Inovio Pharmaceuticals, ISA Pharmaceuticals, Juvaris Biotherapeutics, NewLink Genetics, Northwest Biotherapeutics, NovaRx, OncoThyreon, Oncovir, Oxford BioMedica, Prima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology Data
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment type
5.1.1 Prophylactic
5.1.2 Therapeutic
5.1.3 Y-o-Y Growth Analysis, By Cancer Type
5.1.4 Market Attractiveness Analysis, By Cancer type
5.1.5 Market Share Analysis, By Cancer Type
5.2 Cancer Type
5.2.1 Introduction
5.2.2 Prostate Cancer
5.2.3 Cervical Cancer
5.2.4 Colorectal Cancer
5.2.5 Throat Cancer
5.2.6 Others
5.2.7 Y-o-Y Growth Analysis, By Cancer Type
5.2.8 Market Attractiveness Analysis, By Cancer type
5.2.9 Market Share Analysis, By Cancer Type
5.3 Vaccine Type
5.3.1 Introduction
5.3.2 Tumour cell Vaccines
5.3.3 Protein or Peptide Vaccines
5.3.4 Genetic Vaccines
5.3.4.1 DNA Vaccines
5.3.4.2 RNA Vaccines
5.3.5 Dendritic cell Vaccines
5.3.6 other Vaccines
5.3.7 Y-o-Y Growth Analysis, By Vaccine Type
5.3.8 Market Attractiveness Analysis, By Vaccine Type
5.3.9 Market Share Analysis, By Vaccine Type
5.4 End Users
5.4.1 Introduction
5.4.2 Cancer Treatment Centers
5.4.3 Research Institutes
5.4.4 Y-o-Y Growth Analysis, By End User
5.4.5 Market Attractiveness Analysis, By End User
5.4.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment Type
6.1.3.3 By Cancer Type
6.1.3.4 By Vaccine Type
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment Type
6.1.4.3 By Cancer Type
6.1.4.4 By Vaccine Type
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment Type
6.1.5.3 By Cancer Type
6.1.5.4 By Vaccine Type
6.1.5.5 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Merck & co
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Dendreon
8.3 Glaxosmithkline
8.4 AstraZeneca plc
8.5 Aduro BioTech
8.6 MedImmune
8.7 Sanofi
8.8 Galena Biopharma
8.9 Ubivac
8.10 Oxford Biomedica
8.11 Immunofrontier Inc
8.12 Oncovir Inc
8.13 Immune Cell Therapy (ICT)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
